21
Feb

Carlsbad, CA’s Isis Pharmaceuticals is touting mid-stage results for its in-development spinal muscular atrophy treatment, setting its sights on a Phase III study and sending its shares up about 15%.

…read more

Source: Isis gears up for Phase III with Biogen-partnered antisense drug

    

0 No comments